Rita C Silveira1, Renato S Procianoy2. 1. Department of Pediatrics, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Neonatology Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil. 2. Department of Pediatrics, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Neonatology Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil. Electronic address: rprocianoy@gmail.com.
Abstract
OBJECTIVE: Therapeutic hypothermia reduces cerebral injury and improves the neurological outcome secondary to hypoxic ischemic encephalopathy in newborns. It has been indicated for asphyxiated full-term or near-term newborn infants with clinical signs of hypoxic-ischemic encephalopathy (HIE). SOURCES: A search was performed for articles on therapeutic hypothermia in newborns with perinatal asphyxia in PubMed; the authors chose those considered most significant. SUMMARY OF THE FINDINGS: There are two therapeutic hypothermia methods: selective head cooling and total body cooling. The target body temperature is 34.5 °C for selective head cooling and 33.5 °C for total body cooling. Temperatures lower than 32 °C are less neuroprotective, and temperatures below 30 °C are very dangerous, with severe complications. Therapeutic hypothermia must start within the first 6h after birth, as studies have shown that this represents the therapeutic window for the hypoxic-ischemic event. Therapy must be maintained for 72 h, with very strict control of the newborn's body temperature. It has been shown that therapeutic hypothermia is effective in reducing neurologic impairment, especially in full-term or near-term newborns with moderate hypoxic-ischemic encephalopathy. CONCLUSION: Therapeutic hypothermia is a neuroprotective technique indicated for newborn infants with perinatal asphyxia and hypoxic-ischemic encephalopathy.
OBJECTIVE: Therapeutic hypothermia reduces cerebral injury and improves the neurological outcome secondary to hypoxic ischemicencephalopathy in newborns. It has been indicated for asphyxiated full-term or near-term newborn infants with clinical signs of hypoxic-ischemicencephalopathy (HIE). SOURCES: A search was performed for articles on therapeutic hypothermia in newborns with perinatal asphyxia in PubMed; the authors chose those considered most significant. SUMMARY OF THE FINDINGS: There are two therapeutic hypothermia methods: selective head cooling and total body cooling. The target body temperature is 34.5 °C for selective head cooling and 33.5 °C for total body cooling. Temperatures lower than 32 °C are less neuroprotective, and temperatures below 30 °C are very dangerous, with severe complications. Therapeutic hypothermia must start within the first 6h after birth, as studies have shown that this represents the therapeutic window for the hypoxic-ischemic event. Therapy must be maintained for 72 h, with very strict control of the newborn's body temperature. It has been shown that therapeutic hypothermia is effective in reducing neurologic impairment, especially in full-term or near-term newborns with moderate hypoxic-ischemicencephalopathy. CONCLUSION: Therapeutic hypothermia is a neuroprotective technique indicated for newborn infants with perinatal asphyxia and hypoxic-ischemicencephalopathy.
Authors: Christina L Nemeth; Gabrielle T Drummond; Manoj K Mishra; Fan Zhang; Patrice Carr; Maxine S Garcia; Sydney Doman; Ali Fatemi; Michael V Johnston; Rangaramanujam M Kannan; Sujatha Kannan; Mary Ann Wilson Journal: Nanomedicine Date: 2017-06-30 Impact factor: 5.307
Authors: Juan Huang; Wei Liu; Desislava Met Doycheva; Marcin Gamdzyk; Weitian Lu; Jiping Tang; John H Zhang Journal: Free Radic Biol Med Date: 2019-07-03 Impact factor: 7.376
Authors: Clémence Disdier; Jiyong Zhang; Yuki Fukunaga; Yow-Pin Lim; Joseph Qiu; Andre Santoso; Barbara S Stonestreet Journal: Int J Dev Neurosci Date: 2017-10-25 Impact factor: 2.457
Authors: James K Stanford; Drew S Morgan; Nicholas A Bosworth; Georgio Proctor; Tianwen Chen; Trace T Palmer; Punam Thapa; Bradley J Walters; Douglas E Vetter; Robert D Black; Lesco L Rogers; Christopher Spankovich Journal: Otol Neurotol Date: 2021-03-01 Impact factor: 2.311